Position in NUVB
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$7,447,440
-$3,875,643 QoQ
Shares Held
1,736,000
+37.4% QoQ
Ownership
0.499%
of shares outstanding
% of Portfolio
0.24%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NUVB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ARMISTICE CAPITAL, LLC holds $1,388,824,976 across 55 Biotechnology names. NUVB ranks #33 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TVTX |
Travere Therapeutics, Inc.
|
4,897,417 | $145,502,259 | |
| 2 | PTCT |
Ptc Therapeutics, Inc.
|
2,074,449 | $141,332,210 | |
| 3 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
264,583 | $138,501,263 | |
| 4 | AGIO |
Agios Pharmaceuticals, Inc.
|
2,716,000 | $91,882,280 | |
| 5 | IMVT |
Immunovant, Inc.
|
3,564,916 | $88,552,513 | |
| 6 | INCY |
Incyte Corp
|
656,817 | $61,819,616 | |
| 7 | DYN |
Dyne Therapeutics, Inc.
|
3,175,110 | $57,564,744 | |
| 8 | CYTK |
Cytokinetics Inc
|
764,538 | $50,390,699 |
All Filings in NUVB
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $7,447,440 | 1,736,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $11,323,083 | 1,263,737 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $8,495,200 | 2,296,000 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $975,000 | 500,000 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||